RECRUITING

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

Talk to us

Conditions

Non-Small Cell Lung Cancer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.

Official Title

A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer

Quick Facts

Study Start:2022-11-01
Study Completion:2033-09-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05170204

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Reference Study ID Number: BO42777 https://forpatients.roche.com/
CONTACT
888-662-6728
global-roche-genentech-trials@gene.com

Principal Investigator

Clinical Trials
STUDY_DIRECTOR
Hoffmann-La Roche

Study Locations (Sites)

University of South Alabama; Mitchell Cancer Institute
Mobile, Alabama, 36604
United States
Southern California Kaiser Permanente
San Diego, California, 92108
United States
Rocky Mountain Cancer Centers - Lone Tree
Lone Tree, Colorado, 80124
United States
Mount Sinai Medical Center; Comprehensive Cancer Center
Miami Beach, Florida, 33140
United States
University Of Michigan
Ann Arbor, Michigan, 48109
United States
Oregon Health Sciences Uni
Portland, Oregon, 97239
United States
Northwest Cancer Specialists, P.C.
Tigard, Oregon, 97223
United States
Hillman Cancer Center;Medical Oncology
Pittsburgh, Pennsylvania, 15232
United States
Thompson Cancer Survival Center
Knoxville, Tennessee, 37916-2305
United States
Baptist Cancer Center
Memphis, Tennessee, 38120
United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030-4009
United States
Mays Cancer Center, UT Health San Antonio
San Antonio, Texas, 78229-4427
United States
Virginia Cancer Specialists (Fairfax) - USOR
Fairfax, Virginia, 22031
United States

Collaborators and Investigators

Sponsor: Hoffmann-La Roche

  • Clinical Trials, STUDY_DIRECTOR, Hoffmann-La Roche

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-11-01
Study Completion Date2033-09-01

Study Record Updates

Study Start Date2022-11-01
Study Completion Date2033-09-01

Terms related to this study

Additional Relevant MeSH Terms

  • Non-Small Cell Lung Cancer